Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-007 first-line metastatic NSCLC study
2023-503376-24-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing MK-2870 + pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoint: Overall Survival. Planned start Mar 2024; status: authorised.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503376-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503376-24-00.